Information Provided By:
Fly News Breaks for March 31, 2015
Mar 31, 2015 | 07:32 EDT
UBS called the Horizon Pharma (HZNP) deal for Hyperion Therapeutics (HPTX) a nice, strategic fit and one that was accretive. The firm believes the numbers for Horizon's core business remain too low and will have to come up and that management will continue to bring in smart, strategic, accretive assets. UBS reiterated its Buy rating and raised its price target to $30 from $24 on Horizon Pharma shares.
News For HZNP;HPTX From the Last 2 Days
There are no results for your query HZNP;HPTX
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.